Funded Projects

Explore our currently funded projects. You may search with all three fields, then focus your results by applying any of the dropdown filters. After customizing your search, you may download results and even save your specific search for later.

Reset
Project # Project Title Research Focus Area Research Program Administering IC Institution(s) Investigator(s) Location(s) Year Awarded
1R44DA059302-01
Development of an Opioid Sparing Therapeutic to Minimize Opioid Use Disorder and Tolerance in the Treatment of Pain Cross-Cutting Research Small Business Programs NIDA AMALGENT THERAPEUTICS, LLC MEYN, MALCOLM A Greenville, NC 2023
NOFO Title: PHS 2022-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
NOFO Number: PA-22-176
Summary:

Managing the risks and benefits of opioid medications can be difficult. Although prescription opioids alleviate pain for some patients, serious adverse effects include opioid use disorder. There is a critical, unmet need for new technologies that significantly minimize the opioid doses needed for effective relief from moderate to severe pain. This project will develop a novel combination treatment containing a small amount of morphine along with pramipexole, a drug approved by the U.S. Food and Drug Administration for Parkinson’s disease and restless legs syndrome that reduces the reward-seeking behavior associated with opioids. The research will conduct safety studies to enable testing in human research participants.
1R44NS119036-01
Development of a novel analgesic for mixed inflammatory and neuropathic pain states Cross-Cutting Research Small Business Programs NINDS ANABIOS CORPORATION GHETTI, ANDREA San Diego, CA 2021
NOFO Title: HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 – Clinical Trial Not Allowed)
NOFO Number: RFA-NS-20-011
Summary:

As prescription opioid drug abuse and overdose-related deaths continue to skyrocket in the United States, the need for new and more effective non-addictive pain drugs to treat chronic pain remains critical. This research is conducting studies in animal models of a small molecule that has high potential to treat chronic pain conditions associated with neuropathy and/or inflammation. The goal of this project is to conduct dosing and other studies leading up to an animal model study of the potential drug in a toxicology study for 28 days. Results may lead to Investigative New Drug regulatory clearance to begin clinical studies to validate the potential drug’s efficacy and safety.
1R43DA058614-01
Combination Therapeutic for Chronic Opioid Use Disorder Relapse Cross-Cutting Research Small Business Programs NIDA APHIOS CORPORATION CASTOR, TREVOR P Woburn, MA 2023
NOFO Title: PHS 2022-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
NOFO Number: PA-22-176
Summary:

Side effects from taking the opioid receptor blocker naltrexone make it difficult for patients to adhere to treatment with this medication for opioid use disorder. Cannabidiol (CBD), a bioactive ingredient of cannabis, is not an opioid and is non-psychoactive. Previous research shows that CBD blocks opioid-seeking behaviors, craving, and withdrawal. This project will develop tiny particles containing CBD and low-dose naltrexone. The research will determine if this combined version of CBD and naltrexone helps people stay in treatment and prevents relapse without problematic side effects. 
2R44DA049640-02
Virtual Reality as a Opioid Sparing Intervention for Acute Postoperative Pain Management Cross-Cutting Research Small Business Programs NIDA APPLIEDVR, INC MADDOX, WILLIAM TODD (contact); AYAD, SABRY ; SUK, MICHAEL Los Angeles, CA 2019
NOFO Title: HEAL Initiative: America’s Startups and Small Businesses Build Technologies to Stop the Opioid Crisis (R43/R44 - Clinical Trial Optional)
NOFO Number: RFA-DA-19-019
Summary:

Millions of Americans undergo surgery each year, with fewer than half of patients reporting adequate postoperative pain relief and approximately 75 percent reporting moderate to severe postoperative pain. Gaps in postoperative pain management that lead to the unnecessary introduction and over-prescription of opioids continue to exacerbate the opioid crisis, but virtual reality (VR) has been demonstrated to be an effective strategy for pain management. This project will enhance and improve the functionality of a VR-based technology, AppliedVR, to provide acute perioperative pain management through a new software-based VR medical device, RelieVRx™. As a non-opioid alternative intended to reduce postoperative pain, RelieVRx can potentially reduce the need for and utilization of opioids in the postoperative setting.
1U01DA055352-01
1/6 HBCD Prenatal Experiences and Longitudinal Development (PRELUDE) Consortium Enhanced Outcomes for Infants and Children Exposed to Opioids HEALthy Brain and Child Development Study (HBCD) NIDA ARKANSAS CHILDREN'S HOSPITAL RES INST OU, XIAWEI (contact); ACHESON, ASHLEY ; MCKELVEY, LORRAINE M Little Rock, AR 2021
NOFO Title: HEAL Initiative: HEALthy Brain and Child Development Study (Collaborative U01- Clinical Trial Not Allowed)
NOFO Number: RFA-DA-21-020
Summary:

The objective of the HEALthy Brain and Child Development (HBCD) Prenatal Experiences and Longitudinal Development (PRELUDE) multi-site consortium is to characterize typical brain development from birth through childhood. All sites in this consortium will measure the influence of key biological and environmental factors on child social, cognitive, and emotional development. Researchers will assess how prenatal exposure to opioids and other substances, as well as other adverse environmental factors, affect brain development and other child health outcomes. The Arkansas Children’s Research Institute site is in a predominantly rural state with the second highest rate of opioid prescriptions in the U.S.